Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

2 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Quantitative proteomics associated with Hirschsprung disease

ABSTRACT: We applied large-scale, quantitative proteomics of human colon tissues from 21 patients using iTRAQ method followed by bioinformatics analysis. Selected findings were confirmed by parallel reaction monitoring (PRM) verification

ORGANISM(S): Homo Sapiens

SUBMITTER: Ting Zhang

PROVIDER: PXD021292 | iProX | Thu Oct 22 00:00:00 BST 2020

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Quantitative Proteomics Reveals Association of Neuron Projection Development Genes ARF4, KIF5B, and RAB8A With Hirschsprung Disease.

Zhang Qin Q Wu Lihua L Bai Baoling B Li Dan D Xiao Ping P Li Qi Q Zhang Zhen Z Wang Hui H Li Long L Jiang Qian Q

Molecular & cellular proteomics : MCP 20201208

Hirschsprung disease (HSCR) is a heterogeneous group of neurocristopathy characterized by the absence of the enteric ganglia along a variable length of the intestine. Genetic defects play a major role in the pathogenesis of HSCR, whereas family studies of pathogenic variants in all the known genes (loci) only demonstrate incomplete penetrance and variable expressivity for unknown reasons. Here, we applied large-scale, quantitative proteomics of human colon tissues from 21 patients using isobaric ...[more]

PMID: 33561610

Similar Datasets

Quantitative Proteomic Analysis of an Alexander Disease Murine Model with Severe Reactive Gliosis

Project description:We performed label-free micro-data-independent acquisition (µDIA) to assay brain proteins from a severe model of Alexander disease (AxD, lethal at postnatal day ~35). Of the 5,005 proteins quantified, we observed upregulation of adipocytokine signaling, PPAR, insulin resistance, and glutathione pathways with concomitant downregulation of platelet activation, ether lipid synthesis, and steroid biosynthesis pathways. To validate these DIA results, we setup a targeted parallel reaction monitoring-mass spectrometry assay (PRM-MS) for selected proteins with altered relative concentrations. The PRM-MS assays confirmed the upward or downward relative concentration differences in 16/16 (100%) of the proteins targeted, with 15/16 (94%) of these proteins reaching statistical significance (P-value < 0.05).

2021-11-30 | PXD021884 | Pride

Identification and validation of stage-associated serum biomarkers in colorectal cancer_discovery phase A2_bis

Project description:Colorectal cancer (CRC) is one of the most prevalent and lethal cancer diseases worldwide. Here, we aimed to identify and quantify CRC serum biomarkers by combining a robust label-free quantification procedure followed of two consecutive steps of targeted parallel reaction monitoring (PRM) for biomarker validation in a fully inclusive proteomic strategy. For the discovery phase pooled serum samples were used for shotgun proteomics and label-free quantification. On the identification phase, 116 potential biomarkers were selected based on their statistical significance and their relative expression in disease stages respect to healthy stage and their functional relation with cancer progression. Verification phase was conducted in 2 steps. In the first step, 318 peptides from 116 proteins were used for PRM verification giving place to 23 PRM-quantifiable, potential CRC biomarkers. In a second step, 7 peptides corresponding to CO9, APOC3, CRP, THSB1, ECM1 and IGF2 proteins were reproducibly confirmed by PRM in every CRC stage for these unfractionated samples. Finally, a different cohort composed by individual serum samples was used in the final validation phase. In individual serum samples, 5 peptides belonging to 4 proteins were consistently quantified and validated. ROC analyses indicated that peptides GWVTDGFSSLK and LCNNPTPQFGGK were suitable candidates for predicting the separation between control and CRC patients. Two assays for absolute quantification of significant peptides in serum samples were established using AQUA peptides. In conclusion, a set of serum peptides were validated by PRM as potential biomarkers for differentiating control from CRC patients.

2022-03-01 | PXD010458 | Pride

Identification and validation of stage-associated serum biomarkers in colorectal cancer_discovery B2

2022-03-01 | PXD010309 | Pride

Identification and validation of stage-associated serum biomarkers in colorectal cancer_discovery phase H

2022-02-28 | PXD010351 | Pride

Identification and validation of stage-associated serum biomarkers in colorectal cancer_discovery phase C

2022-03-01 | PXD010328 | Pride

Identification and validation of stage-associated serum biomarkers in colorectal cancer_discovery phase D rep

2022-03-01 | PXD010343 | Pride

Highly multiplexed quantification by targeted mass spectrometry to triage protein candidate biomarkers in plasma

Project description:Despite improvements in capabilities of proteomics technologies, the introduction of new plasma-based protein biomarkers for clinical use remains low. One reason is the cumbersome requirement to test thousands of protein candidates in follow-up quantitative verification studies. We sought to evaluate internal standard triggered parallel reaction monitoring (IS-PRM) in the context of biomarker verification by developing a method to quantify 5,176 peptides (1,314 proteins) as candidate biomarkers for early detection of breast cancer. Method performance was characterized in a response curve showing large linear range (4 orders of magnitude) and good repeatability (median CV 7.7%). The method was applied to pools of cancer and control human plasma, detecting 893 proteins and qualifying 164 candidates to advance for further evaluation. The method shows good quantitative performance, greatly expanding the capabilities for quantification of large numbers of proteins, and is well suited for large scale relative quantification of protein sets.

2022-06-29 | PXD028306 | Pride

Shotgun mass-spectrometry of HL-60 cell proteins for spectrum library development

Project description:ATRA-induced differentiation of HL-60 cells was studied using targeted mass-spectrometry including selected reaction monitoring (SRM) and parallel reaction monitoring (PRM) approach. PRM experiment was performed in time-course manner, without peptide standards usage. PRM data was inspected in Skyline 3.1 software. In order to check peptide identity we developed spectrum library based on shotgun mass-spectrometry data, which has been obtained for HL-60 cells protein samples at 0, 3, 24, 48 and 96h after ATRA treatment.

2017-11-09 | PXD006421 | Pride

Large-Scale Targeted Proteomics Using Internal Standard Triggered-Parallel Reaction Monitoring

Project description:Development, implementation, and evaluation of a new data acquisition scheme called internal standard triggered-parallel reaction monitoring (IS-PRM) to increase the scale of targeted quantitative experiments while retaining high detection and quantification performance. All the details about the dataset, the associated sample preparation and liquid chromatography coupled to tandem mass spectrometry methods, and the data processing procedures are provided in the manuscript by Gallien et al., entitled "Large-Scale Targeted Proteomics Using Internal Standard Triggered-Parallel Reaction Monitoring", Molecular and Cellular Proteomics.

2016-02-09 | PXD001731 | Pride

Large-Scale Targeted Proteomics Using Internal Standard Triggered-Parallel Reaction Monitoring

2017-03-31 | MSV000080832 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data